The FDA is removing black box warnings from hormone replacement therapy (HRT) products used to treat menopause symptoms, marking a significant shift in how the agency views the safety and benefits of these medications. On November 10, the U.S. Department of Health and Human Services (HHS) announced the decision, which is based on updated research showing that HRT can provide long-term health benefits when started within a decade of perimenopause onset .

What Warnings Are Being Removed?

The FDA is removing black box warnings for several serious health conditions that were previously listed on HRT labels. Black box warnings are the most serious type of warning the FDA can place on a medication, typically reserved for drugs with significant safety risks. According to FDA Commissioner Marty Makary and colleagues, the agency is removing warnings related to cardiovascular disease, stroke, breast cancer, and probable dementia from HRT products . However, the warning for endometrial cancer risk with systemic estrogen products will remain in place.

The decision also includes other label changes designed to provide more nuanced guidance. The FDA is removing recommendations that doctors prescribe the lowest effective dose for the shortest duration, and it is revising safety data to reflect risks specific to each formulation of HRT. For topical vaginal products, the agency is emphasizing safety findings relevant to local vaginal use rather than applying broad warnings about systemic exposure .

What Does the Research Actually Show?

The FDA's decision is grounded in clinical evidence that has accumulated over decades. In a landmark article published in JAMA, Makary and colleagues cited several key studies supporting the benefits of HRT when used appropriately. A 2008 study of 343 women found that short-term hormone therapy administered for 2 to 3 years in the postmenopausal years may have protective effects against cognitive impairment later in life. Additionally, a 1980 study of 327 women aged 50 to 74 years found that the risk of hip or lower forearm fracture was 50 to 60 percent lower in women who had used estrogen for 6 years or longer compared with women who had not used hormone therapy .

A 1991 study supported unopposed oral estrogen as protective against coronary events in postmenopausal women, suggesting cardiovascular benefits rather than the risks previously emphasized in black box warnings . These findings represent a substantial body of evidence that has shifted the scientific consensus on HRT safety and efficacy.

Why Did the Black Box Warning Exist in the First Place?

The original black box warnings on HRT products were largely driven by results from the Women's Health Initiative (WHI) study, a major randomized controlled trial conducted in the early 2000s. That study raised concerns about increased risks of breast cancer, cardiovascular disease, and stroke in women using HRT. However, researchers and clinicians have since argued that the WHI findings were misinterpreted or overgeneralized, particularly because the study included older women and those who started HRT many years after menopause onset, which may not reflect the typical patient profile for HRT use today.

"A male-dominated medical profession has minimized the symptoms of menopause, and as a result, women's health issues have not received the attention that they deserve. Women deserve the same rigorous science as is used for men," said Marty Makary, FDA Commissioner.

Marty Makary, FDA Commissioner at the U.S. Department of Health and Human Services

The fear created by the black box warning has had real consequences for patients. Many women prescribed HRT have avoided filling their prescriptions due to concerns about safety, leading to significant underutilization of a treatment that could improve their quality of life and long-term health outcomes .

How to Discuss HRT Options With Your Doctor

If you are experiencing menopause symptoms or are concerned about long-term health risks like bone loss or cardiovascular disease, here are key steps to take when considering hormone replacement therapy:

• Assess Your Symptom Severity: Discuss with your doctor which menopause symptoms are affecting your quality of life, including hot flashes, night sweats, vaginal dryness, mood changes, and sleep disruption.
• Review Your Personal Health History: Share your complete medical history, including any family history of cancer, cardiovascular disease, or blood clots, as these factors influence whether HRT is appropriate for you.
• Explore Formulation Options: Ask your doctor about different types of HRT available, including systemic hormone therapy, topical vaginal products, and localized treatments, since different formulations carry different risk profiles.
• Discuss Timing and Duration: Talk about when to start HRT relative to your menopause transition and how long you might use it, as the FDA now emphasizes that timing of initiation matters for safety and benefit.
• Understand Individual Risk Factors: Work with your doctor to identify which specific warnings apply to you personally, rather than assuming all HRT carries the same risks.

What Are the Remaining Safety Concerns?

While the FDA is removing most black box warnings, important caveats remain. The American Society of Clinical Oncology (ASCO) has emphasized that systemic HRT remains contraindicated for people who previously had breast cancer, particularly those with hormone receptor-positive disease, or other estrogen-responsive cancers such as certain gynecologic cancers, due to an increased risk of cancer recurrence . The endometrial cancer warning for systemic estrogen products is also being retained.

Additionally, the American Urological Association released new guidelines in April 2025 recommending that clinicians offer local, low-dose vaginal estrogen for vulvovaginal discomfort, dryness, dyspareunia (painful intercourse), and recurrent urinary tract infections (UTIs) in patients with genitourinary syndrome of menopause . This distinction between systemic and local vaginal treatments is important, as they carry different safety profiles.

"Systemic hormone replacement therapy remains contraindicated for people who previously had breast cancer, particularly those with hormone receptor-positive disease, or other estrogen-responsive cancers, due to an increased risk of cancer recurrence," warned the American Society of Clinical Oncology.

American Society of Clinical Oncology, in response to HHS decision

What Do Health Organizations Say About This Change?

The response to the FDA's decision has been mixed among health organizations. While groups like ASCO and the Society for Women's Health Research have expressed support for removing the black box warning, they also urge caution and call for more research to understand how hormone therapy may impact long-term health outcomes . These organizations recognize the potential benefits of HRT while emphasizing the importance of individualized decision-making and continued monitoring of safety data.

The removal of the black box warning represents a significant moment in women's health policy, reflecting decades of accumulated research and a recognition that the previous warnings may have prevented many women from accessing a treatment that could meaningfully improve their health and quality of life during and after menopause.